AI assistant
Sending…
Spyre Therapeutics, Inc. — Director's Dealing 2016
Apr 12, 2016
32226_dirs_2016-04-12_6c8513cf-0112-4078-87b4-e1921a524d3e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2016-04-12
Reporting Person: Cox Russell J. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-04-12 | Common Stock | P | 7000 | $10 | Acquired | 7000 | Direct |
More from Spyre Therapeutics, Inc.
Regulatory Filings
2026
May 29
Regulatory Filings
2026
May 5
Interim / Quarterly Report
2026
May 5
Regulatory Filings
2026
Apr 16
Regulatory Filings
2026
Apr 13
Regulatory Filings
2026
Apr 13
Regulatory Filings
2026
Apr 13
Proxy Solicitation & Information Statement
2026
Apr 10
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 4